Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Shaman issued U.S. patents for type II diabetes compounds

June 4, 1997

U. of California discloses mammalian EPO-BP

June 4, 1997

ACE inhibitors inhibit bone resorption in vitro

June 3, 1997

AGE inhibitor described by Kissei

June 3, 1997

Positive efficacy profile reported for Zonagen's Vasomax

May 30, 1997

Ono reports AGE inhibitors and antioxidants

May 29, 1997

Kyoto describes ACAT/lipid peroxidation inhibitors

May 29, 1997

Merck & Co. acquires majority share of Gentili

May 28, 1997

Nissan Chem. reveals new antidiabetic agents

May 28, 1997

MP-52 to be developed worldwide by HMR

May 27, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.